Nursing Pharmacology Chapter 33-34:  Anticancer Drugs

Previous Page Next Page
Section Table of Contents

Site Table of Contents

Previous Page Next Page
Section Table of Contents

Site Table of Contents

References

  1. Chabner BA General Principles of Cancer Chemotherapy Chapter 60 in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011.

  2. Sausville EA Longo DL Chapter 103e Principles of Cancer Treatment, in Harrison's Online   (Dennis L. Kasper, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo,  J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 19th edition, The McGraw-Hill Companies, Inc. 2015.

  3. Chu E Sartorelli AC Cancer Chemotherapy Chapter 54 in Basic & Clinical Pharmacology, 13 e (Katzung BG  and Trevor AJ) The McGraw-Hill Companies, 2015 (on-line edition)

  4. Chabner BA Bertino J Cleary J Ortiz T Lane A Supko JG Ryan Chapter 61:  Cytotoxic Agents in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011.

  5. Chabner BA Barnes J Neal J Olson E Mujagic H Sequist L Wyham Wilson Longo DL Mitsiades C Richardson P  Chapter 62:  Targeted Therapies:  Tyrosine Kinase Inhibitors, Monoclonal Antibodies and Cytokines  in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011.

  6. Moy B Goss P Lee RJ Smith M  Chapter 63:  Natural Products in Cancer Chemotherapy:  Hormones and Related Agents. in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th edition (Brunton LL Chabner BA Knollmann BC, eds; Brunton LL, ed; Blumenthal DK  Murri N Hilal-Dandan R, assoc eds, Knollmann BC, consulting ed, on-line edition) The McGraw-Hill Companies, 2011.

  7. Rosenberg SA Robbins PF Phan G Feldman SA Kochenderfer JN  Chapter 14:  Cancer Immunotherapy  in Principles & Practice of Oncology (DeVita, JR VT Lawrence TS Rosenberg SA, eds) 10e Wolters Kluwer Health 2015.

  8. Tew KD Chapter 17:  Alkylating Agents  in Principles & Practice of Oncology (DeVita, JR VT Lawrence TS Rosenberg SA, eds) 10e Wolters Kluwer Health 2015.

  9. Collins JM Cancer Pharmacology Chapter 29 in Abeloff's Clinical Oncology (Niederhuber JE Armitage JO Doroshow JH Kastan MB Tepper JE, eds)  5e Elsevier Churchill Livingstone, Philadelphia, PA 2014.

  10. SEER Training Modules, National Cancer Institute, Types of Chemotherapy Drugs:  Alkylating agents http://training.seer.cancer.gov/treatment/chemotherapy/types.html accessed April 10, 2016.

  11. Noll DM Mason TM Miller PS Formation and Repair of Interstrand Cross-Links in DNA Chem Rev.  106(2):  277-302 February 2006. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2505341/

  12. Roche VF Chapter 37 Cancer and Chemotherapy (in Foye's Principles of Medicinal Chemistry 7e Lemke TL Williams DA Roche VF Zito SW, eds) Wolters Kluwer | Lippincott Williams & Wilkins, 2013.

  13. Kantarjian H Cortes J Chapter 101 Chronic Myeloid Leukemia in in Abeloff's Clinical Oncology (Niederhuber JE Armitage JO Doroshow JH Kastan MB Tepper JE, eds)  p. 1944 5e Elsevier Churchill Livingstone, Philadelphia, PA 2014.

  14. AN X Tiwari AK Sun Y Ding P-R Ashby JR CR Chen Z-S  BCR-ABLE tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia:  A review  Leukemia Research  34(10):  1255-1268, 2010.

  15. BCR-ABL tyrosine-kinase inhibitor https://en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase_inhibitor; https://www.ncbi.nlm.nih.gov/pubmed/20537386

  16. Vac cinationist  Imatinib in its binding site. https://commons.wikimedia.org/wiki/File:Imatinib_in_its_binding_site.svg

  17. Druker BJ Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapeies (Part I:  Imatinib (Gleevec:  A Targeted Cancer Therapy)  https://www.youtube.com/watch?v=d6xU3bgBLIw  March 29, 2010

  18. Gerson SL Bulgar AD Weeks LD Chabner BA  Chapter 14:  Part A:  Alkylating Agents:  Classical Alkylating Agents in Cancer Chemotherapy and Biotherapy:  Principles and Practice, 5e (Chabner BA & Longo DL, eds) 2011.

  19. Kirschner RH Esterly JF Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia Cancer 27:  1074-1080 May 1971. http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197105)27:5<1074::AID-CNCR2820270511>3.0.CO;2-G/pdf

  20. EL Fakih R Shah N Nieto Y Chapter 12:  Autologous Hematopoietic Progenitor Cell Transplantation in The MD Anderson Manual of Medical Oncology (Kantarijian HM and Wolff RA, eds; Shpall EJ Section ed) 3e McGraw-Hill Eduation 2016.

  21. Talebi T Stem Cell Transplantation https://www.youtube.com/watch?v=_Y-P6mJ2ncY (additional information:  www.HemOnc101.com)

  22. A Rad Hematopoiesis (human) diagram https://commons.wikimedia.org/wiki/File:Hematopoiesis_simple.svg

  23. Tsuruta T Recent Advances in Hematopoietic Stem Cell Gene Therapy.  Chapter 5 in Innovations in Stem Cell Transplantation (Demirer T, ed) 2013 (Figure 1)  http://www.intechopen.com/books/innovations-in-stem-cell-transplantation/recent-advances-in-hematopoietic-stem-cell-gene-therapy

  24. LiverTox:  Clinical and Research Information on Drug-Induced Liver Injury--Sinusoidal Obstruction Syndrome (Veno-occulsive Disease) United States National Library of Medicine. http://livertox.nih.gov/Phenotypes_sinus.html

  25. Mohty M Malard F Abecassis M Aerts E Alaskar AS Alijurf M Arat M Bader P Baron F Bazarbachi A Blaise D Ciceri F Corbacioglu S Dalle J-H Duarte RF Fukada T Huynh A Masszi T Michallet M Nagler A NiChonghaile M Pagluica T Peters C Petersen FB Richardson PG Ruutu T Savani BN Wallhut E Yakoub-Agha I Carreras E Special Report:  Sinusoidal obstruction syndrome/veno-occlusive diease:  current situation and perspectives-a position statement frome the European Society for Blood and Marrow Transplantation (EBMT).  Bone Marrow Transplanation 50:  781-789 2015. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4456788/

  26. Yager JD Hepato and Renal Toxicology Johns Hopkins Bloomberg School of Public Health http://ocw.jhsph.edu/courses/publichealthtoxicology/PDFs/Lecture6_Yager.pdf 2008

  27. Appelbaum FR Chapter 139e Hematopoietic Cell Transplantation in Harrison's Online   (Dennis L. Kasper, Anthony S. Fauci, Stephen L. Hauser, Dan L. Longo,  J. Larry Jameson, Joseph Loscalzo, Eds.),  Harrison's Principles of Internal Medicine, 19th edition, The McGraw-Hill Companies, Inc. 2015.

  28. Brammer JE Andersson BS Hosing C Chapter 13:  Allogeneic Transplantation in Kantarjian HM Wolff RA The MD Anderson Manual of Medical Oncology, 3e, 2016.in the context of bone marrow transplantation

  29. Wellstein A Giaccone G Atkins MB Sausville EA Cytotoxic Drugs Chapter 66 in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 13th edition (Brunton LL (Editor-in-chief)  Hilal-Dandan R Knollmann BC, eds) The McGraw-Hill Companies, 2018.

  30. Vincent Lecture#2 Alkylating Agents for Cancer https://www.youtube.com/watch?v=UWLmu6BI2Cw

 

Disclaimer

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.